Carfilzomib-induced Thrombotic Microangiopathy: A Case Based Review.
Journal
Hematology/oncology and stem cell therapy
ISSN: 2589-0646
Titre abrégé: Hematol Oncol Stem Cell Ther
Pays: Saudi Arabia
ID NLM: 101468532
Informations de publication
Date de publication:
23 05 2023
23 05 2023
Historique:
received:
12
05
2020
accepted:
11
07
2020
medline:
19
6
2023
pubmed:
1
8
2020
entrez:
1
8
2020
Statut:
epublish
Résumé
Carfilzomib is an irreversible proteasome inhibitor currently approved for the treatment of relapsed multiple myeloma. It has been implicated as a cause of thrombotic microangiopathy (TMA) in several case reports. The incidence, risk factors, and treatment of carfilzomib-related TMA remain unclear. Here we describe the clinical presentation and outcome of a 58-year-old man with biopsy-proven TMA that occurred following treatment with carfilzomib-based therapy. We also reviewed the published literature with regard to the incidence, risk factors, treatment options, and outcome of carfilzomib-related TMA.
Identifiants
pubmed: 32735793
pii: j.hemonc.2020.07.001
doi: 10.1016/j.hemonc.2020.07.001
doi:
Substances chimiques
carfilzomib
72X6E3J5AR
Proteasome Inhibitors
0
Oligopeptides
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM